JERUSALEM, May 25 (Reuters) - Israel’s Zetiq, a unit of Bio-Light Ltd (BOLT.TA), said on Monday it successfully completed clinical trials for its technology for the early detection of cervical cancer.
Bio-Light’s shares were up 24.4 percent at 1.33 shekels in afternoon trading in Tel Aviv.
According to the results, the testing can detect pre-cancerous cells in 90 percent of patients, Zetiq said in a statement, noting it was higher than the traditionally used Pap test and similar to that for the HPV virus, which can cause cervical cancer.
“The results of this trial confirm that Zetiq has the potential to develop novel and effective products for early diagnosis of cervical cancer and probably other indications,” said Ami Eyal, Bio-Light’s chief executive.
“The company plans to complete the development of its product for screening to early identify cervical cancers, and to proceed towards international collaborations and product commercialisation”.
Cervical cancer is the second leading cause of cancer in women worldwide. Early identification of the disease greatly increases the survival rate.
Screen tests for cervical cancer are performed routinely in the western world, and have a large market that in the United States alone surpasses $1.5 billion. In developing countries there is no effective screening test available to identify cervical cancer. (Reporting by Steven Scheer, editing by Will Waterman)